MLTX Trading Analysis - 11/18/2026 02:19 PM โ€” TRU-SENTIMENT

MLTX (MoonLake Immunotherapeutics Class A Ordinary Share) at $11.01. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $17,245 vs put $0. RSI 42.4.

TRU-SENTIMENT ยท DeltaNeutral

MLTX Trading Analysis - 11/18/2026 02:19 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

MLTX (MoonLake Immunotherapeutics Class A Ordinary Share) at $11.01. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $17,245 vs put $0. RSI 42.4.

Symbol
MLTX
Price
$11.01
Article bias (separate from True Sentiment)
bullish
Conviction
low
Published
2026-11-18 14:19:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Call Volume: $17,245 (100.00%) Put Volume: $0 (0.00%) Total: $17,245

Methodology: Delta 40-60 only. Sentiment: Bullish. 169 call contracts vs 0 puts, 3 call trades. Pure directional conviction is call-heavy but on only $17.2K notional (filter ratio 0.9% of 346 options). This suggests minor bullish positioning, diverging from bearish technical alignment. Options flow is the only sentiment source; no X posts retrieved.

Note: True Sentiment shows 100% call dollar volume but total analyzed directional flow is tiny vs avg daily volume.

Key Statistics: MLTX

$10.99 -1.26%
52-Week Range
$9.46 - $23.29
Market Cap
$935.33M
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
0.06
Next Earnings
N/A
Avg Volume
$1.25M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-3.66
Market cap$935.33M
Shares outstanding85.1M

Dividend

Dividend yield0.00%

Risk & range

Beta0.06
52-week low$9.46
52-week high$23.29
Historical volatility80.3%

Ownership & trading

Institutional ownership10.5%
Average daily volume1.7M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

Recent general-knowledge context for MLTX (MoonLake Immunotherapeutics, a clinical-stage biotech focused on inflammatory diseases):

  • Company presented positive interim Phase 2 skin biopsy data for nanobody IL-17 inhibitor at a major dermatology conference, reinforcing pipeline optimism.
  • Management outlined upcoming pivotal trial readout timeline, with a key catalyst expected in the coming quarters rather than next 25 days.
  • No earnings release scheduled within the immediate 25-day window based on typical fiscal calendar; fiscal year end is 2025-12-01 per fundamentals.
  • Low institutional ownership (10.51%) suggests limited street coverage and potential for volatile retail-driven moves on news.
  • Headlines reflect long-term pipeline promise, but the embedded data shows near-term technical softness and tiny bullish options flow โ€” news context does not override the current data divergence.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

  • Trailing EPS is -3.66; company is unprofitable with no trailing PE (null) and no forward PE (null).
  • Revenue growth, gross/operating/net margins, ROE, and free cash flow are all null โ€” not disclosed in dataset.
  • Debt/equity, PEG ratio, and price/book are null; cannot assess leverage or relative valuation vs peers.
  • Market cap is $935,325,930 with 85,107,000 shares out; 52-week range is $9.46 to $23.29 (current ~$11.13 near low third).
  • Institutional holding is only 10.51%; beta is 0.06 (very low market correlation).
  • Historical volatility is 80.32%; average volume 1,663,000; dividend yield 0.00%.
  • Analyst consensus, target mean price, and number of opinions are null โ€” no street target context.
  • Fundamentals (no earnings, low institutional base) diverge from the bullish options sentiment and show a speculative small-cap biotech with weak measurable fundamentals.

Current Market Position

Current price per indicators is $11.13 (2026-11-17 close). Minute bars show 2026-11-17 open $11.72 dropping to low $10.93 and close $11.13; 2026-11-18 intraday traded $11.65 down to $10.99 then $11.01 at 13:50. Recent daily action: peaked $13.90 on 2026-11-11, faded to $11.70 (11-16) and $11.13 (11-17). Intraday momentum is weak/sideways near $11.00โ€“$11.02 with volume spikes (19,123 at 13:45 11-18).

Support
$10.54 (BB lower)
Resistance
$11.98 (SMA20/BB mid)
30d Low
$9.48
30d High
$13.90
SMA50
$11.76

Technical Analysis

Technical Indicators

RSI (14)
42.42
MACD
0.09 / Sig 0.08
SMA5
12.40
SMA20
11.98
SMA50
11.76
BB Upper
13.41
BB Lower
10.54
ATR14
0.88

Price ($11.13) is below SMA5 ($12.40), SMA20 ($11.98), and SMA50 ($11.76) โ€” bearish alignment, no golden cross. RSI 42.42 shows weak momentum, not oversold. MACD histogram +0.02 is marginally bullish but negligible. Bollinger mid $11.98 / lower $10.54; price sits in lower band. 30d range $9.48โ€“$13.90: price is ~14% above low, ~20% below high.

True Sentiment Analysis (Delta 40-60 Options)

Call Volume: $17,245 (100.00%) Put Volume: $0 (0.00%) Total: $17,245

Methodology: Delta 40-60 only. Sentiment: Bullish. 169 call contracts vs 0 puts, 3 call trades. Pure directional conviction is call-heavy but on only $17.2K notional (filter ratio 0.9% of 346 options). This suggests minor bullish positioning, diverging from bearish technical alignment. Options flow is the only sentiment source; no X posts retrieved.

Note: True Sentiment shows 100% call dollar volume but total analyzed directional flow is tiny vs avg daily volume.

Key Price Levels (Observational Only)

Support
$10.54 (BB lower)
Resistance
$11.76 (SMA50)
Resistance 2
$11.98 (SMA20)
Upper Band
$13.41
30d Low
$9.48

Interactive charts load with JavaScript. This text is the crawlable summary.